Cargando…

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. METHODS: PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were se...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Fatima, Saleem, Anam, Samuel, Sehar Saba, Sarfraz, Zouina, Sarfraz, Azza, Sarfraz, Muzna, KC, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256371/
https://www.ncbi.nlm.nih.gov/pubmed/37335635
http://dx.doi.org/10.1097/MD.0000000000033978
_version_ 1785057089628930048
author Hassan, Fatima
Saleem, Anam
Samuel, Sehar Saba
Sarfraz, Zouina
Sarfraz, Azza
Sarfraz, Muzna
KC, Manish
author_facet Hassan, Fatima
Saleem, Anam
Samuel, Sehar Saba
Sarfraz, Zouina
Sarfraz, Azza
Sarfraz, Muzna
KC, Manish
author_sort Hassan, Fatima
collection PubMed
description Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. METHODS: PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines. RESULTS: A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women. CONCLUSION: While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms.
format Online
Article
Text
id pubmed-10256371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-102563712023-06-10 Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy Hassan, Fatima Saleem, Anam Samuel, Sehar Saba Sarfraz, Zouina Sarfraz, Azza Sarfraz, Muzna KC, Manish Medicine (Baltimore) 7400 Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. METHODS: PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines. RESULTS: A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women. CONCLUSION: While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms. Lippincott Williams & Wilkins 2023-06-09 /pmc/articles/PMC10256371/ /pubmed/37335635 http://dx.doi.org/10.1097/MD.0000000000033978 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 7400
Hassan, Fatima
Saleem, Anam
Samuel, Sehar Saba
Sarfraz, Zouina
Sarfraz, Azza
Sarfraz, Muzna
KC, Manish
Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title_full Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title_fullStr Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title_full_unstemmed Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title_short Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
title_sort neurokinin 1/3 receptor antagonists for menopausal women: a current systematic review and insights into the investigational non-hormonal therapy
topic 7400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256371/
https://www.ncbi.nlm.nih.gov/pubmed/37335635
http://dx.doi.org/10.1097/MD.0000000000033978
work_keys_str_mv AT hassanfatima neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT saleemanam neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT samuelseharsaba neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT sarfrazzouina neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT sarfrazazza neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT sarfrazmuzna neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy
AT kcmanish neurokinin13receptorantagonistsformenopausalwomenacurrentsystematicreviewandinsightsintotheinvestigationalnonhormonaltherapy